COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Study of the Litx™ System Combined With Chemotherapy in Patients With Colorectal Liver Metastases

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00083785
Recruitment Status : Completed
First Posted : June 3, 2004
Last Update Posted : April 11, 2007
Information provided by:
Light Sciences LLC

Brief Summary:
The purpose of this study is to determine whether the Litx™ system is safe and effective in combination with chemotherapy in the treatment of liver metastasis arising from colorectal cancer. Litx™ is a next-generation photodynamic therapy platform in which the drug, talaporfin sodium (LS11), is activated by light from the light-emitting diode (LED)-based light infusion device, inserted directly into the tumor through the skin prior to treatment.

Condition or disease Intervention/treatment Phase
Liver Metastasis Colorectal Neoplasms Liver Neoplasms Neoplasm Metastasis Drug: Talaporfin sodium (LS11) Device: LED-based light infusion device Device: Light emitting diodes (LED) Procedure: Photodynamic therapy Procedure: Phototherapy Procedure: Chemotherapy Phase 2

Detailed Description:

Patients that provide Informed Consent and satisfy the Eligibility Criteria will undergo CT or Ultrasound guided percutaneous placement of a single, two, three, or four Light Sources depending on their tumor characteristics. No more than 4 Light Sources will be used at a single treatment. The Light Sources may be used in a single lesion or in multiple lesions.

Following radiographic confirmation of Light Source placement, patients will receive an intravenous dose of LS11 at 40 mg/m². Fifteen minutes to 1 hour following completion of LS11 administration, delivery of 200 J/cm at 20 mW/cm light energy will begin. The Light Source will then be manually removed and the patients will be observed for acute complication of Light Source removal. Precautions for protection from external light exposure should be instituted beginning with the LS11 administration and be maintained as defined throughout the study period. On day 3 following Litx™ treatment the patient will receive a standard chemotherapy with Irinotecan or Oxaliplatin with or without 5FU and /or leucovorin for metastatic colorectal cancer. On day 30+5 and day 60+5 the patient will undergo clinical assessment and the tumor mass will be imaged using contrast enhanced spiral CT for determination of volume and radius of PDT necrosis.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 25 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Safety and Effectiveness of Treating Cancers With the Litx™ System and Chemotherapy. Section A: Phase II Safety and Effectiveness Study in Patients With Liver Metastases From Colorectal Cancer
Study Start Date : May 2004

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients with metastatic liver lesions from colorectal disease
  • Biopsy proven evidence of colorectal cancer
  • Patients with 4 or fewer lesions greater than 1 cm and with no single lesion greater than 7 cm in maximum diameter
  • Age greater than or equal to 18 years
  • Patients must be able to sign informed consent
  • Life expectancy greater than or equal to 3 months
  • ECOG performance status 0-2
  • Patients with extrahepatic disease in addition to their hepatic metastases may be eligible
  • Must have recovered from the toxicity from any prior antineoplastic therapy

Exclusion Criteria:

  • Patients who are candidates for complete surgical resection
  • Pregnancy or breast-feeding. A negative pregnancy test (urine or serum) is required prior to enrollment
  • Known uncontrollable serious reactions such as anaphylaxis, to the contrast agents used in this study
  • PT or PTT greater than 1.5X control
  • Platelet count less than 100,000
  • WBC less than 2500/mm
  • Neutrophils less than 2000/mm
  • Hemoglobin less than 9 g/dL
  • Liver enzymes (AST, ALT, GGT, alkaline phosphatase) greater than 3 X ULN
  • Total bilirubin greater than 1.5 X ULN
  • Serum creatinine greater than 2.5 X ULN
  • Patients who have been treated with either AVASTIN™ (Bevacizumab) or ERBITUX™ (Cetuximab) within the previous 4 weeks (28 days)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00083785

Layout table for location information
United States, Washington
Virginia Mason Medical Center
Seattle, Washington, United States, 98101
Sponsors and Collaborators
Light Sciences LLC
Additional Information:
Layout table for additonal information Identifier: NCT00083785    
Other Study ID Numbers: LSC-OL003
First Posted: June 3, 2004    Key Record Dates
Last Update Posted: April 11, 2007
Last Verified: April 2007
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasm Metastasis
Neoplasms, Second Primary
Liver Neoplasms
Colorectal Neoplasms
Neoplastic Processes
Pathologic Processes
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Liver Diseases
Intestinal Neoplasms
Gastrointestinal Neoplasms
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases
Antineoplastic Agents
Photosensitizing Agents
Dermatologic Agents